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Letter to the Editor
Response to “New Delhi Metallo-b-lactamase (NDM-1):
an emerging Threat Among Enterobacteriaceae”
Subhash C Arya,* Nirmala Agarwal
To the Editor,
We compliment Professor Hsueh on the meticu-
lous dissertation on emergence and dissemination
of the New Delhi metallo-β-lactamase (NDM-1)
gene.1
In all probability, there has already been ex-
tensive cryptic dissemination of NDM-1 in several
cities in the Indian subcontinent. Of the 100 sam-
ples collected from sewers across Delhi, isolates
that carried NDM-1 were detected in 11 samples.2
No standardized phenotypic test is available for
NDM-1 detection and molecular methods such
as real-time polymerase chain reaction (PCR) are
necessary. Non-availability of a phenotypic test for
detection of NDM-1 is a major obstacle towards
any therapeutic or preventive interventions against
NDM-1 carriage and dissemination.
A standardized phenotypic test is essential for
poor countries where laboratory services are a
neglected component with little appreciation of
their role in patient care and management, disease
control, public health, and disease surveillance.3
In developing countries, a large number of labo-
ratories, even in large cities, lack a high level 
of competence.4 The majority of diagnostic 
laboratories would probably not be able to iden-
tify any NDM-1 carriage in their premises, and
real-time PCR of NDM-1-specific genes would by
no means be feasible. NDM-1 diagnosis would
only be achieved through simpler test versions
that are not contingent on costly equipment and
trained personnel.
Phenotypic diagnosis of isolates that carry
metallo-β-lactamases (MBLs) has been performed
using the modified Hodge test, MBL Etest, or
Imipenem-DETA Double Synergy Test.5 None of
these tests is specific for NDM-1. Furthermore, a
turbidity meter and the standard reference stain
Escherichia coli ATCC 25922 are essential for 
carrying out the modified Hodge test, and false-
positive results are known with some isolates that
do not produce carbapenemases.5 Any positive
result requires confirmation by real-time PCR.
Simpler assay formats have been useful to
monitor antimicrobial resistance in staphylococci
and Mycobacterium tuberculosis. For example, 30 μg
cefoxitin disks are useful to screen methicillin-
resistant Staphylococcus aureus (MRSA) in routine
laboratories and have been popular in healthcare
centers at various locations.4,6 Cefoxitin screening
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combined with PCR for the mecA gene have
emerged as the best phenotypic assay among the
four MRSA detection phenotypic tests.7 A highly
sensitive and simple-to-use system to detect M.
tuberculosis and rifampin resistance directly from
sputum has been evaluated in the field in
Uganda and Vietnam. The Cepheid Gene Xpert
System’s MTB/RIF (M. tuberculosis/resistance to
rifampicin) assay, which is an integrated hands-
free sputum-processing and real-time PCR system
with rapid on-demand, near-patient technology,
has shown great potential to simultaneously 
detect M. tuberculosis and rifampin resistance. 
M. tuberculosis could be detected from sputum in
< 2 hours. Furthermore, all the 23 different com-
monly occurring rifampin resistance mutations
were identified as rifampin resistant.8
Philanthropic organizations including inter-
national organizations like the World Health
Organization should spare funds towards devel-
opment and standardization of point-of-care assay
procedures, which resemble those that monitor
methicillin resistance in staphylococci and ri-
fampin resistance in M. tuberculosis, for NDM-1
detection in routine clinical laboratories.
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